NCT00946257View on ClinicalTrials.gov

Subcutaneous Administration of Otelixizumab to T1DM Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 8, 2009

Primary Completion Date

August 1, 2011

Study Completion Date

June 25, 2013

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Otelixizumab

A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.

Trial Locations (6)

1070

GSK Investigational Site, Brussels

1090

GSK Investigational Site, Brussels

2170

GSK Investigational Site, Merksem

3000

GSK Investigational Site, Leuven

4000

GSK Investigational Site, Liège

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY